The purpose of this study is to test the safety and tolerability of an experimental anticancer drug currently known as BGB-16673 for men and women who have B-cell malignancies.

Experimental means that it has not yet been approved by the US Food and Drug Administration (FDA).

BGB-16673 is an oral Bruton tyrosine kinase (BTK) targeted protein degrader, which targets and binds to BTK in the body, inhibiting its activity. BTK in the body allows malignant cells to survive and BTK inhibitors interfere with this process.

This clinical trial is for men and women with gastrointestinal (GI) or genitourinary (GU) cancers who have been diagnosed with a blood clot called a venous thromboembolism (VTE) which can include deep venous thrombosis (DVT) in the leg veins, and/or a pulmonary embolism (PE), which is a clot in the pulmonary artery in the lungs.
   

This clinical trial is for men and women who have Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia.
 
The purpose of this research is to gather information on the safety and effectiveness of PBCAR0191. PBCAR0191 is a new investigational treatment for certain types of blood cancers, such as leukemia and lymphoma, and is made from a type of blood cells known as T cells. 

This clinical trial is for men and women who have advanced hematologic malignancies (blood cancers) that may be treated with a blood stem cell transplant.
   
The purpose of this research study is to find out if an experimental therapy, Orca-T, can be safely given as a blood stem cell transplant to patients with blood cancers and pre-cancerous conditions and if Ora-T results in less graft vs host disease (GVHD) than standard blood stem cell transplants.
   

This study is being done to improve outcomes and treatment options in patients with chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).

Patients will be treated with a combination of oral pills containing zanubrutinib and venetoclax. Depending on how each patient responds to treatment with the initial study drugs, a third drug called obinutuzumab may be added. Obinutuzumab is given by an intravenous (IV) infusion.

This is a clinical trial for adults under the age of 70 years of age, who have been diagnosed with a brain tumor called a glioblastoma (GBM).
   
The purpose of this study is to see how safe the study drug IGV-001 is when given with standard of care therapy and to see if it works in slowing glioblastoma tumor regrowth. Additionally, the study will compare how well IGV-001 + SOC therapy works compared to a placebo + standard of care therapy.   

The purpose of this study is to collect information about patients with breast cancer, as well as studying their blood and/or other tissue in the laboratory to better study the cause and treatment of breast cancer.

Through this study, investigators hope to find new markers that will help prevent, detect, and manage patients with breast cancer. By studying the clinical course of patients with cancers of the breast and by performing additional laboratory studies, we hope to learn more about what causes these cancers and help identify new treatments for patients.

The purpose of this study is to investigate the role of circulating tumor cells (CTCs) in patients with prostate cancer. Patients who have prostate cancer can develop metastases where the cancer spreads outside the prostate into other organs. It is believed that this occurs from tumor cells that circulate in the bloodstream.

This is a clinical trial for adults diagnosed with relapsed (has come back) or refractory (has not responded to treatment) acute myeloid leukemia (AML).

The goal of Phase 1 of this study is to test the safety and tolerability of up to 5 different doses of the investigational medication UCART123 and to find the best dose of UCART123 that can be given to patients with AML that is relapsed or refractory.   

This clinical trial is for men and women with B-cell Non-Hodgkin Lymphoma (NHL).
   
The purpose of this study is to study is to assess the safety and effectiveness of odronextamab in destroying participant's cancer cells. Odronextamab is an investigational drug, which means it has not yet been approved by the U.S. Food and Drug Administration (FDA).